AJR Women's Imaging Online
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maksimovic, O.
Right arrow Articles by Horger, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maksimovic, O.
Right arrow Articles by Horger, M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Hotlight (NEW!)
Right arrow
What's Hotlight?
DOI:10.2214/AJR.09.2744
AJR 2010; 194:5-14
© American Roentgen Ray Society

Pictorial Essay

Evaluation of Response in Malignant Tumors Treated With the Multitargeted Tyrosine Kinase Inhibitor Sorafenib: A Multitechnique Imaging Assessment

Olga Maksimovic1, Christina Schraml1, Joerg T. Hartmann2, Michael Bitzer3, Claus D. Claussen1, Jan Pintoffl1 and Marius Horger1

1 Department of Diagnostic and Interventional Radiology, Eberhard-Karls-University, Hoppe-Seyler-Str. 3, 72076 Tübingen, Germany.
2 Department of Oncology, Hematology, Rheumatology, Immunology, and Pulmonology, Eberhard-Karls-University, Tübingen, Germany.
3 Department of Hepatology and Gastroenterology, Eberhard-Karls-University, Tübingen, Germany.

OBJECTIVE. The purpose of this article is to illustrate the characteristic changes induced in different tumor types by the multitargeted tyrosine kinase inhibitor sorafenib.

CONCLUSION. Sorafenib reduces tumor perfusion and thereby induces necrosis and often hemorrhage. Malignant tumors treated with sorafenib undergo both morphologic and functional changes; however, the morphologic changes are less frequent and inadequate for early evaluation of response. Therefore, imaging tools accurately assessing hemorrhage and decrease in tumor perfusion with subsequent necrosis should be the mainstay in monitoring targeted therapy agents.

Keywords: hepatocellular carcinoma • multitargeted tyrosine kinase inhibitor • renal cell carcinoma • sorafenib • therapy response monitoring


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2010 by the American Roentgen Ray Society.